CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02...

|By:, SA News Editor

CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02 reported for Q1 2012. Net losses were $2.3M versus losses of $4.2M during the prior year period. R&D expenses increased by 25% Y/Y, largely due to the increased level of activity associated with conducting Phase III clinical studies. Shares -0.5% AH.